Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes

作     者：George Frimpong Boafo Yejiao Shi Qingqing Xiao Kosheli Thapar Magar Makhloufi Zoulikha Xuyang Xing Chao Teng Emmanuel Brobbey Xiaotong Li Xiaohong Jiang Xiaochun Wang Yi Yang Samuel Kesse Wei He George Frimpong Boafo;Yejiao Shi;Qingqing Xiao;Kosheli Thapar Magar;Makhloufi Zoulikha;Xuyang Xing;Chao Teng;Emmanuel Brobbey;Xiaotong Li;Xiaohong Jiang;Xiaochun Wang;Yi Yang;Samuel Kesse;Wei He

作者机构：Shanghai Skin Disease HospitalTongji University School of MedicineShanghai 200443China Department of PharmaceuticsSchool of PharmacyChina Pharmaceutical UniversityNanjing 211198China Institute of Translation MedicineShanghai UniversityShanghai 200444China 

出 版 物：《Chinese Chemical Letters》 (中国化学快报（英文版）)

年 卷 期：2022年第33卷第10期

页      面：4600-4604页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(Nos.81872823 and 82073782) the Double First-Class(No.CPU2018PZQ13)of the China Pharmaceutical University the Shanghai Science and Technology Committee(No.19430741500) the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(No.zdsys-202103) 

主　　题：Breast cancer Daunorubicin Cytarabine Co-delivery Liposomes 

摘      要：Breast cancer is the most prevalent cancer in women,and it was hard to prevent or diagnose at an early ***,it is imperative to develop advanced therapeutics for effective ***,a targeted daunorubicin(DNR)and cytarabine(ara-C)co-delivery system was developed by modifying the ara-C loaded liposomes(LIP-ara-C)with the hyaluronic acid-DNR(HA-DNR)*** co-assembled hybrid nanoparticles(HA-DNR/LIP-ara-C HNPs)exhibited good serum and storage stability with an average diameter of approximately 100 *** specifically binding to the CD44 receptors that overexpressed on cancer cells,these HNPs could be uptake via endocytosis and accumulate intracellularly,in which an optimized DNR and ara-C combination at a molar ratio of 1:5 could generate enhanced synergistic effects with reduced dose-related toxicity on cancer cells.